Abatacept (Orencia) and Medicare

The short answer

• The infusion is covered by Part B. You pay 20% of the cost with no yearly limit — roughly $8,900 a year for a mid-weight adult. A Medicare supplement policy covers that 20% and brings it down to almost nothing.
• The weekly shot is covered by Part D. Your costs stop at $2,100 for the whole year in 2026, whatever the medication costs.

So on paper the shot wins by a wide margin. The problem is getting a plan that covers it — and that is the part of this page worth reading carefully.

Most drug plans do not cover the self-injection

We went through the drug plan formularies CMS published for 2026 and counted. Of 5,490 Medicare drug plans, only about 23% cover Orencia’s self-injection at all.

And it is much worse in the place most people look. Among standalone drug plans — the kind you buy alongside Original Medicare — 5 out of 367 cover it. That is 1.4%. The plans that do cover it are overwhelmingly Medicare Advantage plans.

Which produces a genuinely awkward situation. The cheaper route is the shot. But the coverage that makes the infusion affordable — Original Medicare plus a supplement — comes with a standalone drug plan that almost certainly will not pay for the shot. And the plans that do cover the shot are the ones that make you get permission before every infusion and limit which doctors you can see.

What to do about it: do not assume. Put “Orencia” into Medicare’s plan finder with the exact form you take, and see which plans in your area actually list it. If none do, the infusion is your route, and then a supplement policy matters enormously.

The two forms, side by side

Infusion figures use Medicare’s published payment rate and the 750 mg dose, which is what an adult between 60 and 100 kg receives. Under 60 kg the dose is 500 mg and your 20% is closer to $6,000; over 100 kg it is 1,000 mg and closer to $11,900. The first year has two extra doses. The infusion visit itself is billed separately, and you pay 20% of that too.

Which is cheaper for you

• Original Medicare, no supplement, and you can find a plan covering the shot: the shot, by roughly $6,800 a year. This is the best outcome and the hardest to arrange.
• Original Medicare with a supplement policy: the infusion, by roughly $1,800 a year. The supplement absorbs the 20%, so you are left with about the Part B deductible — while the shot would still cost you the full $2,100.
• Original Medicare, no supplement, no plan covering the shot: the infusion, and about $8,900 a year with nothing stopping it if your weight or dose changes. This is the situation to actively avoid, and the way to avoid it is a supplement policy.
• Medicare Advantage: the plan sets its own charges and everything stops at the plan’s yearly limit. But read the next section, because with Advantage the price is not the problem.

Whether the shot or the infusion is right for you is a medical question. They are not identical in practice — the infusion is given by a nurse who is watching you, the shot is weekly and you do it yourself. But if money is the only thing pushing you one way, say so at your next appointment.

Nobody has to approve the infusion — under Original Medicare

If you are on Original Medicare and you get abatacept as an infusion, there is no prior authorization. Nothing to submit, nothing to wait for, and nobody can require you to fail a different medication first. Original Medicare is not permitted to do either.

Medicare Advantage plans are permitted to do both. This is not theoretical — one large national insurer’s 2026 policy lists Orencia infusion as “non-preferred” and requires members to try one of six other infused medications first. Your rheumatologist may have chosen abatacept for a specific reason, and the plan can still require the other drug first.

For the shot, approval is nearly universal — required by 92% of the plans that cover it at all, and nine in ten put it on the specialty tier. That is not a reason to pick one drug plan over another. It is a reason to start the paperwork early and never assume a renewal is automatic.

If you are turned down, appeal. Across Medicare Advantage in 2024 only about one denial in nine was appealed — and 81% of those appeals succeeded.

There is no cheaper version yet

Some biologics now have biosimilars — the same medicine from a different company, at a lower price. Abatacept does not. As of August 2026 the FDA has not approved any abatacept biosimilar.

One is in the pipeline: the FDA accepted an application in February 2026. Accepted is not approved, and there is no date. So unlike some other infusions, there is currently no cheaper version to ask your doctor about — which makes the coverage decisions above matter more, not less.

Things that surprise people

• The Orencia copay card does not work if you have Medicare. Federal law prohibits it, and that includes Medicare Advantage and Medigap. It is not the plan being difficult.
• But the manufacturer’s foundation is a different thing, and it does help Medicare patients. The Bristol Myers Squibb Patient Assistance Foundation can supply the medication free if your income is below their limit, you have spent at least 3% of your household income on prescriptions this year, and you have applied for Extra Help and been turned down. That last requirement trips people up — apply for Extra Help first, and keep the denial letter.
• Where you get infused changes what you pay. A hospital outpatient department adds a facility fee that a doctor’s office does not. If your bill feels higher than it should, ask where the infusion is being billed from.
• The whole $2,100 can land in January. Medicare has a program that spreads it across twelve months instead, interest-free — but you have to sign up. It is called the Medicare Prescription Payment Plan.
• Your dose depends on your weight. If your weight crosses 60 kg or 100 kg, your dose changes and so does your 20%. This surprises people mid-year.
• Extra Help. If your income is modest it can bring Part D costs to nearly nothing, and it is the gateway to the manufacturer foundation above. Badly underused.

Free help, from someone who is not paid a commission

Given how few drug plans cover the self-injection, this is a medication where sitting down with a counselor and checking your actual local plans is worth real money. It is free, and they earn nothing whichever plan you choose.

• Washington: SHIBA — insurance.wa.gov/shiba or 1-800-562-6900
• Any other state: SHIP — shiphelp.org
• Check which plans cover it where you live — medicare.gov/plan-compare
• Spread the January cost — medicare.gov/prescription-payment-plan
• Extra Help — ssa.gov/medicare/part-d-extra-help

Why isn’t my infusion covered by the $2,100 cap?

Because the $2,100 cap only applies to Part D, and an infusion is paid by Part B. The cap Congress created covers drugs you pick up and take yourself. A medication a nurse or doctor gives you is paid under Part B instead, where you owe 20% of the cost every time and there is no annual ceiling at all.

It is the same Medicare, often the same drug, and frequently the same disease. The rulebook is chosen by who puts the medicine in you. Almost everything written about the cap leaves this out, so people on infusions read that their costs are now limited, and then the bills keep coming.

A worked example. If Medicare’s approved amount for a year of your infusions is $18,000, you owe about $3,600 — this year, next year, and every year you stay on it. The $2,100 cap does not apply to any of it.

Four things do put a ceiling on Part B costs:

• A Medicare supplement (Medigap) policy, which pays the 20% for you. This is the main one, and the window to buy one closes six months after you enroll in Part B in most states.
• A Medicare Advantage plan’s yearly out-of-pocket maximum, which applies to everything the plan covers — though it comes with prior authorization attached.
• QMB, a Medicare Savings Program that eliminates the 20% entirely. This is the one people are not told about — and note that Extra Help, which people are told about, does nothing for a Part B drug.
• Full Medicaid, or retiree coverage that pays after Medicare.

Related

• Medicare and your medication — look up any other medication and compare your coverage options
• Why your medication needs permission first
• Tocilizumab (Actemra) and Medicare — the same infusion-versus-shot question, with a different answer
• Rheumatoid arthritis guide
• Where you get infused changes the bill — the same infusion costs more at a hospital, and the bill nobody warns you about

Where these figures come from

1. Orencia prescribing information — FDA, via DailyMed. Adult rheumatoid arthritis dosing: intravenously by weight (500 mg under 60 kg, 750 mg for 60–100 kg, 1,000 mg over 100 kg) at weeks 0, 2 and 4, then every 4 weeks; or 125 mg subcutaneously once weekly, with the intravenous loading dose optional.
2. Medicare payment limit for abatacept (HCPCS J0129): $45.859 per 10 mg — CMS Part B ASP pricing file effective July 1 – September 30, 2026. A 750 mg dose is 75 units, so $3,439 per infusion; 13 maintenance infusions is $44,713 allowed, of which your 20% is about $8,943.
3. Orencia 125 mg prefilled syringe and ClickJect wholesale acquisition cost of $1,517.65 each — Bristol Myers Squibb published pricing disclosure. Weekly dosing gives an annual list cost of about $78,900.
4. Part D annual out-of-pocket cap of $2,100 and deductible of $615 for 2026 — CMS Final CY2026 Part D Redesign Program Instructions. Cap established by the Inflation Reduction Act of 2022. The 2027 cap is $2,400.
5. Part B annual deductible of $283 and 20% coinsurance with no annual limit for 2026 — CMS, “2026 Medicare Parts A & B Premiums and Deductibles,” November 2025; Social Security Act §1833(a).
6. Formulary coverage of Orencia 125 mg: on formulary for 1,245 of 5,490 plans (22.7%), of which 92.0% require prior authorization and 90.5% place it on the specialty tier; 5 of 367 standalone prescription drug plans (1.4%) cover it — analysis of the CMS Monthly Prescription Drug Plan Formulary File, released July 29, 2026. Counted by plan, not weighted by how many people are enrolled in each.
7. Orencia subcutaneous listed as a self-administered drug and therefore excluded from Part B — Medicare Administrative Contractor self-administered drug exclusion articles, including Noridian JF (A53033, which covers Washington State), Noridian JE (A53032), Novitas (A53127), First Coast (A52571), Palmetto (A53066) and WPS (A52800).
8. Step therapy permitted for Medicare Advantage Part B drugs, and not permitted in Original Medicare — 42 CFR §422.136. The 2026 step therapy example is drawn from a national insurer’s published Part B step therapy preferred drug list, revised July 2026.
9. No prior authorization program in Original Medicare covers physician-administered drugs — CMS, Prior Authorization and Pre-Claim Review Initiatives.
10. No FDA-approved abatacept biosimilar as of August 2026 — FDA biosimilar product information, current as of August 4, 2026. One application was accepted for review in February 2026; acceptance is not approval.
11. Medicare Advantage appeal rates and outcomes for 2024 (11.5% of denials appealed, 80.7% of appeals overturned) — KFF analysis of CMS data, 2026.
12. Copay card exclusion for federal healthcare program beneficiaries — Orencia copay program terms and conditions; federal Anti-Kickback Statute, 42 U.S.C. §1320a-7b. Manufacturer foundation eligibility — Bristol Myers Squibb Patient Assistance Foundation application.
13. Medicare spending: abatacept under Part B, $930 million across 33,154 beneficiaries in 2024; Orencia under Part D, $754 million across 17,660 beneficiaries — CMS Medicare drug spending dashboards, updated June 2026.

About this page

Written and reviewed by Alison Bays, MD, MPH, board-certified rheumatologist. Figures are current for 2026 and were last checked in August 2026.

This is educational information, not advice — not medical, legal, financial or insurance advice, and not a substitute for talking to your doctor or your plan. Nothing is sold here. No insurance is sold here, no plan is recommended, and neither this page nor its author is paid by any insurance company, plan, pharmaceutical manufacturer or broker. This page is not affiliated with, endorsed by, or connected to Medicare, the Centers for Medicare & Medicaid Services, or any government agency.

Found something wrong? Please tell us.